Endothelial precursor cell cross-match using Tie-2-enriched spleen cells

• Verfasst von: Daniel, Volker [VerfasserIn]
• Verfasst von: Süsal, Caner [VerfasserIn]
• Verfasst von: Scherer, Sabine [VerfasserIn]
• Verfasst von: Tran, Thuong Hien [VerfasserIn]
• Verfasst von: Gombos, Petra [VerfasserIn]
• Verfasst von: Trojan, Karina [VerfasserIn]
• Verfasst von: Sadeghi, Mahmoud [VerfasserIn]
• Verfasst von: Morath, Christian [VerfasserIn]
• Verfasst von: Opelz, Gerhard [VerfasserIn]
• Titel: Endothelial precursor cell cross-match using Tie-2-enriched spleen cells
• Verf.angabe: Volker Daniel, Caner Süsal, Sabine Scherer, Hien Tran, Petra Gombos, Karina Trojan, Mahmoud Sadeghi, Christian Morath, Gerhard Opelz
• E-Jahr: 2017
• Jahr: 19 September 2017
• Umfang: 16 S.
• Fussnoten: Gesehen am 02.08.2018
• Titel Quelle: Enthalten in: Clinical transplantation
• Ort Quelle: Oxford [u.] : Wiley-Blackwell, 1999
• Jahr Quelle: 2017
• Band/Heft Quelle: 31(2017,12) Artikel-Nummer e13118, 16 Seiten
• ISSN Quelle: 1399-0012
• DOI: doi:10.1111/ctr.13118
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: antibodies against endothelial progenitor cells
• Sach-SW: deceased-donor kidney grafts
• Sach-SW: pre-formed EPC antibodies
• Sach-SW: spleen cells
• Sach-SW: XM-ONE
• K10plus-PPN: 1578206073

Abstract

Background Non-HLA antibodies against human endothelial progenitor cells (EPC) in pre-transplant recipient serum can have a deleterious influence on the graft. EPC enriched from peripheral blood have been commonly used for EPC cross-matching. In the present study, we describe cross-matches using EPC enriched from fresh or frozen-thawed spleen cell preparations, thereby widening the sample source for deceased-donor cross-matching and retrospective studies. Methods EPC cross-matches were performed retrospectively using spleen cells and the flow cytometric XM-ONE cross-match test kit. Results Healthy controls (n = 28) showed no IgG antibodies against EPC. When sera of 11 random dialysis patients were studied, 2 patients (18%) exhibited IgG EPC antibodies. When pre-transplant sera of 20 kidney graft recipients with good long-term graft outcome (serum creatinine 1.0 ± 0.2 mg/dL measured 2463 ± 324 days post-transplant) were investigated using frozen-thawed and then separated Tie-2-enriched spleen cells of the original transplant donor, 3 patients (15%) had pre-transplant IgG EPC antibodies. When pre-transplant sera of 5 patients with intra-operative graft loss were studied employing the original donor spleen cells, 4 (80%) patients showed IgG EPC antibodies. Conclusions Cross-matches with spleen cell-derived EPC using the XM-ONE assay are technically possible. Our very preliminary experience suggests clinical relevance.